GLP-1 Receptor Agonist Use Linked to Reduced Risks for Substance Use Disorder MONDAY, March 9, 2026 -- The use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with reduced risks for developing substance use disorders (SUDs), according to a study published online March 4 in The BMJ
Each of our compounds is independently tested by an ISO 17025 accredited lab using the HPLC (High-Performance Liquid Chromatography) method to establish purity above 99% and Mass Spectrometry (MS) to confirm the molecular identity of the compound
2024 | 6:08AM (IST) Manufacturer details 110A, Liberty Plaza, Himayatnagar, Hyderabad-500029 Country of origin: INDIA Expiry on or after: November 2026 In case of any issues, contact us: [email protected]|09240250346 Address: 6th floor, Urmi Corporate Park Solaris, Saki Vihar Road, Andheri East, Mumbai 400071 Was this product description useful
doi: 10.1152/ajpgi.00222.2016 183 RohrbachTDAsgharpourAMaczisMAMontefuscoDCowartLABedossaPet al